Teva Pharmaceuticals USA, Inc., et al. v. Forest Laboratories, Inc., C.A. No. 13-2002 - GMS, July 9, 2015

Morris James LLP
Contact

Teva Pharmaceuticals USA, Inc., et al.  v. Forest Laboratories, Inc., C.A. No. 13-2002 - GMS, July 9, 2015

Sleet, J. The court considers 6 terms from on patent-in-suit.

The patent-in-suit relates to a method of preparing an analgesic pharmaceutical composition for the administration of an NMDA receptor antagonist.

The following terms are considered:

  1. wind-up
  2. diminish or abolish wind-up
  3. for the administration . . . to a human or animal subject for the treatment of     pain (preamble construed not to be limiting)
  4. immediate release form/ immediate release
  5. sustained release form/ sustained release
  6. immediate release for and sustained release form being present in sufficient amounts

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morris James LLP | Attorney Advertising

Written by:

Morris James LLP
Contact
more
less

Morris James LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide